A systematic review found that lactoferrin had the potential as future salivary biomarker for AD.185 However, Gleerup et al. have observed that salivary lactoferrin could not differentiate between neurodegenerative dementias.186 These findings indicated that heterogeneity of cohorts or medications leading to altered saliva production might impact the efficacy of potential biomarkers. The gene discussed is LTF; the disease is Alzheimer disease.